Literature DB >> 34315865

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity.

Adam M Burgoyne1, Kendra R Vann2, Shweta Joshi3, Guillermo A Morales4, Francisco M Vega3,5, Alok Singh3, Dhananjaya Pal3, Aran B Merati1, Tatiana G Kutateladze6, Donald L Durden7,8.   

Abstract

Entities:  

Year:  2020        PMID： 34315865     DOI： 10.1038/s41421-020-0181-z

Source DB:  PubMed          Journal:  Cell Discov        ISSN： 2056-5968            Impact factor:   10.849


× No keyword cloud information.
  1 in total

Review 1.  MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Authors:  Nandini Dey; Brian Leyland-Jones; Pradip De
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.